Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy

Figure 4

(a) Positron-emission tomography-computed tomography (PET/CT) imaging of the chest of a 46-year-old male patient with stage IIIA squamous cell lung cancer before and after the administration of 3 cycles of cisplatin/albumin-bound paclitaxel plus pembrolizumab. The pretreatment scan showed a primary tumor (PT) ( cm; ) in the left upper lobe and enlarged subaortic lymph nodes (LN) ( cm; ) (upper arrow). A scan performed before surgery showed a decrease in size and FDG uptake of both PT ( cm; ) and LN ( cm; ) (lower arrow). (b, c) Multiplex immunofluorescence staining and fields of view (FOVs) selection of the primary tumor and subaortic lymph nodes. (d–f) Densities of stromal T cells (S-CD3+), cytotoxic T cells (S-CD8+), and PD-L1-positive T cells (S-PD-L1+CD3+) were assessed in LN and PT in two regions (center of tumor (CT) and invasive margin (IM)). ; ns; not significant.

(a)

(b)

(c)

(d)

(e)

(f)